Skip to main content
13 April 2021
Last updated:
Tuesday 13 April 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Evernow Publishing Ltd Privacy Policy. Read more.

Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.

The latest MedNous journal. Subscribe to download.

Free featured article

Blank cheque company formed

Friday 9 April 2021
Country

Netherlands

A special purpose acquisition company, known colloquially as a blank cheque company, has been launched by Life Sciences Partners (LSP) of the Netherlands, the first such company to focus exclusively on European biotech. Special purpose acquisition companies, or SPACs, are proliferating on Wall Street, fuelled by low interest rates and a demand from investors for innovative assets.

Read more

UniQure ends safety probe

Tuesday 13 April 2021
Country

Netherlands

UniQure NV has concluded an investigation of a patient who had a preliminary diagnosis of hepatocellular carcinoma (HCC) whilst participating in the gene therapy trial HOPE-B for haemophilia. In a statement issued on 29 March, the company said “it is highly unlikely the HCC was caused by etranacogene dezaparvovec.” The company has shared the data with the US Food and Drug Administration, which put a clinical hold on the trial in December 2020.

Read more

Medigene discovers antigens

Tuesday 13 April 2021
Country

Germany

Medigene AG has reported the discovery of novel immunogenic tumour specific antigens derived from the non-coding regions of the human genome. The German biotech company presented the finding at the virtual annual meeting of the American Association for Cancer Research on 10 April.

Read more

Vaccitech files for IPO

Monday 12 April 2021
Country

United States

Read more

Sanofi acquires Tidal

Monday 12 April 2021
Country

France

Read more

Device using AI is approved

Monday 12 April 2021
Country

United States

Read more

Allcyte raises $6 million for AI platform

Monday 12 April 2021
Country

Austria

Read more

Venture capital merger

Thursday 8 April 2021
Country

United Kingdom

Read more

Artios to collaborate with Novartis

Wednesday 7 April 2021
Country

United Kingdom

Read more

AZ vaccine has side effects

Wednesday 7 April 2021
Country

Netherlands

Read more

Dutch start-up explores virus prophylactic

Wednesday 7 April 2021
Country

Netherlands

Read more

New indication for Sarclisa

Thursday 1 April 2021
Country

France

Read more

Gene therapy for AMD gets funding

Monday 29 March 2021
Country

Netherlands

Read more
Looking for more?

Visit our news section for more articles.

News Our full Mednous news archive Appointments Latest industry appointments Events A list of upcoming industry events

About Mednous

MedNous is a print publication and a website for everyone involved in medical research in Europe.

Read more

Free Article

Bispecific antibody development gains momentum

The Bispecific Approach, interviews with Merus, Genmab and NovalGen

Latest MedNous Issue Highlights

March 2021 edition of MedNous

The Bispecific Approach
Interviews with Merus, 
Genmab and NovalGen

Financial Strategy
Why we should take a second
look at RNA therapeutics
By Gabriele Campi

Coronavirus
New treatments in the pipeline
By Peter Charlish

Gene Therapy
Addressing the challenges
of gene therapy medicinal products
By Paula Salmikangas and Björn Carlsson

 

The latest MedNous journal. Subscribe to download.

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

René Hoet becomes CSO at Montis Biosciences
Wednesday March 31 2021
Pan Cancer T makes board appointments
Wednesday March 31 2021
Björn Englund appointed CEO at Opterion
Wednesday March 31 2021
Sven Zimmermann joins Inotrem
Wednesday March 31 2021
New director at Mission Therapeutics
Wednesday March 31 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.